OriA631 / Oricell - LARVOL DELTA

A novel bi-specific antibody targeting CD39 and PD-L1 for enhanced cancer immunotherapy (AACR 2025) - "This study introduces OriA631-B, a pioneering bi-specific antibody designed to simultaneously engage CD39 and PD-L1...By concurrently targeting CD39-mediated immune suppression and PD-L1-mediated T cell exhaustion, this bi-specific antibody may circumvent resistance mechanisms and enhance T cell engagement with tumor cells, ultimately improving patient outcomes. Further clinical evaluation is warranted to fully assess the therapeutic potential of this innovative bi-specific antibody in cancer immunotherapy."

Oncology • ENTPD1

Enhanced GPC3-chimeric antigen receptor T cells with secreted bi-specific CD39-PD-L1 antibody for improved liver cancer therapy (AACR 2025) - "We previously demonstrated that a bi-specific antibody, OriA631-B, which targets CD39—an enzyme crucial for converting extracellular ATP into adenosine—and PD-L1, yields significant antitumor effects...In a mouse model of liver cancer, GPC3 CAR-T-CD39-VHH-PD-L1-ScFv exhibited superior antitumor activity compared to GPC3 CAR T cells alone. Specifically, while GPC3 CAR T cells inhibited tumor growth, the GPC3 CAR-T-CD39-VHH-PD-L1-ScFv nearly eliminated tumors by day 20, whereas tumors in the GPC3 CAR T group measured around 200 mm³.This enhanced efficacy is attributed to the localized delivery of the bi-specific antibody fragment, which effectively inhibits adenosine signaling and PD-L1-mediated immune checkpoint blockade.Our findings suggest that GPC3 CAR-T-CD39-VHH-PD-L1-ScFv represents a novel therapeutic strategy for liver cancer, offering improved efficacy and potentially reduced side effects associated with systemic antibody administration."

CAR T-Cell Therapy • IO biomarker • Liver Cancer • Oncology • Solid Tumor • ENTPD1 • GPC3

Effect of cancer immunotherapy with CD39/PD-L1 bispecific antibody OriA631-b. (ASCO 2024) - "In summary, OriA631-B demonstrates potential as an innovative immunotherapeutic strategy for cancer treatment by concurrently targeting CD39-mediated immune suppression and PD-L1-mediated T cell exhaustion. Further exploration, including clinical trials, is imperative to fully uncover the therapeutic capabilities of this groundbreaking bispecific antibody in cancer immunotherapy."

Oncology • ENTPD1

Enhanced anti-ovarian cancer efficacy with MSLN-chimeric antigen receptor T cells secreting anti-CD39 antibody. (ASCO 2024) - " We have previously designed OriA631, an antibody antagonist targeting CD39 in VHH format... Our study introduces the innovative therapeutic agent MSLN CAR-T-CD39-VHH, showcasing superior anti-tumor efficacy and the potential for reduced antibody-associated side effects. These findings strongly endorse the application of MSLN CAR-T-CD39-VHH as a promising and impactful therapeutic approach for the treatment of ovarian cancer."

CAR T-Cell Therapy • Clinical • Oncology • Ovarian Cancer • Solid Tumor • ENTPD1 • MSLN

OriA631-B: a first-in class CD39/PD-L1 bispecific antibody unleashing enhanced cancer immunotherapy (SITC 2023) - "By simultaneously targeting CD39-mediated immune suppression and PD-L1-mediated T cell exhaustion, this bispecific antibody holds promise for overcoming resistance mechanisms and acting as a T cell-tumor cell engager, thus improving patient outcomes (figure 6). Further investigations, including clinical trials, are warranted to fully explore the therapeutic potential of this innovative bispecific antibody in the context of cancer immunotherapy."

Oncology • ENTPD1